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The differentiation of insulin-producing h-cells has been investigated in great detail; however, little is known about the factors that
delineate the second-most abundant endocrine lineage, the glucagon-producing a-cell. Here we utilize a novel YAC-based Foxa3Cre
transgene to delete the winged helix transcription factor Foxa2 (formerly HNF-3h) in the pancreatic primordium during midgestation. The
resulting Foxa2loxP/loxP; Foxa3Cre mice are severely hypoglycemic and die within the first week of life. Mutant mice are hypoglucagonemic
secondary to a 90% reduction of glucagon expression. While the number of mature glucagon-positive a-cells is dramatically reduced,
specification of a-cell progenitors is not affected by Foxa2 deficiency. By marker gene analysis, we show that the expression of the a-cell
transcription factors Arx, Pax6, and Brn4 does not require Foxa2 in the transcriptional hierarchy governing a-cell differentiation.
D 2004 Elsevier Inc. All rights reserved.
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During mouse development, dorsal and ventral pancre-
atic primordia first appear as evaginations of the foregut
endoderm on embryonic day (E) 9.0 (Slack, 1995). The
induction of the pancreatic phenotype in the dorsal
pancreatic bud was thought to be dependent upon a
permissive signal from the adjacent notochord (Kim and
Melton, 1998; Kim et al., 1997; Slack, 1995), but more
recent evidence suggests that this signal originates from
blood vessels (Lammert et al., 2001, 2003). In the mouse,
the two pancreatic buds rotate and merge to form the organ
seen in adult animals that comprises exocrine and
endocrine compartments. Development of the endocrine
pancreas is a complex process that requires coordinated
interactions among multiple transcription factors during
different stages of development. It is the precise regulation
of transcription factors that directs endocrine progenitors to0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: kaestner@mail.med.upenn.edu (K.H. Kaestner).give rise to five distinct hormone-producing cell types: a,
h, y, PP, and q cells, which secrete glucagon, insulin,
somatostatin, pancreatic polypeptide, and ghrelin, respec-
tively. At later stages of development, several of these
factors are also required to define and maintain individual
mature cell types (Edlund, 2001; Prado et al., 2004; Slack,
1995; Wilson et al., 2003).
Several transcription factors have been identified based
on their temporally and spatially restricted expression
during pancreatic development (Edlund, 1998; Wilson et
al., 2003). In addition, analysis of mice with targeted
mutations of the genes that encode these factors has
furthered our understanding of islet differentiation. Deletion
of Pdx1, a homeobox gene expressed in pancreatic buds,
leads to an arrest of pancreatic differentiation at a very early
stage (Guz et al., 1995; Jonsson et al., 1994, 1995; Offield et
al., 1996). Mice lacking Neurogenin 3 (Ngn3), a bHLH
transcription factor expressed in the endocrine progenitor
cells, suffer from diabetes due to the absence of all islet cells
(Gradwohl et al., 2000; Gu et al., 2002; Herrera et al., 2002;
Lee et al., 2002a; Schwitzgebel et al., 2000). Furthermore,
the winged-helix transcription factor, Foxa2 [formerly278 (2005) 484–495
Foxa2: 5VCCC-CTG-AGT-TGG-CGG-TGG-T-3V
5VTTG-CTC-ACG-GAA-GAG-TAG-CC-3V
Cre: 5VGCG-GCA-TGG-TGC-AAG-TTG-AAT-3V
5VCGT-TCA-CCG-GCA-TCA-ACG-TTT-3V
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normal h-cell function as its h-cell-specific ablation results
in hyperinsulinemic hypoglycemia (Lantz et al., 2004; Sund
et al., 2001).
In addition to Foxa2, the related winged helix family
members Foxa1 and Foxa3 are expressed at the onset of
definite endoderm development, with Foxa2 being activated
first, followed by Foxa1, and finally Foxa3 (Ang et al.,
1993; Monaghan et al., 1993; Sasaki and Hogan, 1993).
Expression of the Foxa genes persists into adulthood
(Cockell et al., 1995; Wu et al., 1997) and Foxa binding
sites have been identified in the promoters or enhancers of
several genes expressed in the pancreas, including Pdx1 and
preproglucagon (Ben-Shushan et al., 2001; Marshak et al.,
2001; Philippe et al., 1994; Sharma et al., 1997; Wu et al.,
1997). The binding of Foxa proteins to these promoters is of
functional importance in vivo as a-cells lacking Foxa1
express reduced levels of preproglucagon mRNA (Kaestner
et al., 1999; Shih et al., 1999) and Foxa2-deficient h-cells
cannot fully activate transcription of the Pdx1 gene (Lee et
al., 2002b). The Foxa genes are not equivalent, as deletion
of Foxa3 has no apparent consequences for pancreatic gene
expression, in contrast to the situation described for Foxa1
and Foxa2 (Kaestner et al., 1998).
Ablation of Foxa2 in the pancreatic h-cell using Cre
recombinase driven by the rat insulin promoter (Ins.Cre) led
to the surprising finding that Foxa2 is required for the
normal function of h-cells and the expression of the two
subunits of the KATP channel (Lantz et al., 2004; Sund et al.,
2001). While it was demonstrated that Foxa2 contributes to
the maintenance of mature h-cells, it is possible that
deletion of the Foxa2loxP target effected by the Ins.Cre
transgene occurred too late to demonstrate the full effect of
Foxa2 on the initiation of pancreatic development (Sund et
al., 2001). To overcome this limitation, we have derived a
new Cre line, the first to direct Cre expression to the gut
endoderm before the onset of pancreatic differentiation. We
have used this new tool to delete Foxa2 in the embryonic
gut and to uncover a previously unrecognized role for
Foxa2 in pancreatic a-cell development.Hprt (143bp): 5V-GGCCAGACTTTGTTGGATTTG-3V
5V-TGCGCTCATCTTAGGCTTTGT-3V
Preproglucagon (128bp): 5V-TGAGATGAGCACCATTCTGGA-3V
5V-TCCGCAGAGATGTTGTGAAGA-3V
Brn 4 (108bp): 5V-GGCTGATTCATCCACAGGAAG-3V
5V-TTCCAGTACGCCCTTGACACT-3V
Pax 6 (117bp): 5V-AAACAAACGCCCTAGCTCTCC-3V
5V-CCGCCCTTGGTTAAAGTCCTC-3V
Arx (149bp): 5V-TCCGGATACCCCACTTAGCTT-3V
5V-GACGCCCCTTTCCTTTAAGTG-3VMaterials and methods
Targeting vector construction
A yeast artificial chromosome (YAC) encompassing the
mouse Foxa3 (formerly HNF3g or Hnf3g) gene was
modified as described (Hiemisch et al., 1997), with the
exception that we used the Cre coding sequence to replace
exon 2 of Foxa3.
Animals and genotype analysis
Foxa2loxP/loxP mice were derived as previously described
(Sund et al., 2000). All mice were kept on a mixed outbred-CD1 background. Genotyping was performed by PCR
analysis using genomic DNA isolated from the tail of
newborn mice (Sund et al., 2000). Genotyping primers were
as follows:Analytical procedures
Blood glucose values were determined from whole
venous blood using a glucose monitor (Glucometer Elite,
Bayer). To prepare plasma, mice were killed by decapitation
on P1–P3, and plasma obtained by centrifugation. Plasma
glucagon was measured using RIA (University of Pennsyl-
vania Diabetes Center). Since 100 Al of plasma was required
for this assay, plasma from multiple animals of the same
genotype were pooled.
b-Galactosidase detection
Embryos were fixed in 4% paraformaldehyde (PFA) at
48C for 1 h. After fixation, embryos were washed three
times for 10 min in PBS and incubated overnight (O/N) in
staining solution [5 mM K3(Fe(CN))6, 5 mM K4(Fe(CN))6,
2 mM MgCl2, 0.02% NP40, 0.01% sodium deoxycholate,
and 1 mg/ml Bluo-Gal (Gibco) BRL in PBS]. Subsequently,
embryos were washed three times for 10 min in PBS and
postfixed in 4% PFA O/N at 48C. Embryos were washed in
PBS and photographed.
RNA analysis
Total RNA from E18.5 and P1 pancreas was isolated
after homogenization and processed using Trizol (LTI).
Reverse transcription PCR (RT-PCR) analysis was
performed as described (Duncan et al., 1997). A
Stratagene Mx4000 Real-Time PCR machine was used
for the quantitative PCR analysis. Conditions and
primer concentrations suggested by the SYBR Green
Assay protocol were followed. The following forward
and reverse primers were used for amplification (size in
bp):
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Tissues were fixed in 4% PFA overnight at 48C,
embedded in paraffin, cut to 6 Am sections, and applied to
Probe-on Plus slides (Fisher Scientific). Slides were
deparaffinized in xylene and rehydrated through a series
of ethanol washes. Slides were subjected to microwave
antigen retrieval by boiling for 15 min in 10 mM citric acid
buffer (pH 6.0) and allowed to cool for 10 min at room
temperature (RT). All slides were washed in PBS, then
blocked with protein blocking reagent (Immunotech) for 20
min at RT. The primary antibodies were diluted in PBS
containing 0.1% BSA and 0.2% Triton X-100 (PBT) unless
noted otherwise and incubated with the sections overnight at
48C. Slides were washed in PBS and incubated with the
appropriate secondary antibodies diluted in PBT for 2 h at
RT. Slides were washed in PBS, mounted, and examined
using confocal microscopy (Leica). The following primary
antibodies were used at the indicated dilutions: rabbit anti-
Foxa2 (K2 1:2000; a gift from Dr. T. Jessel), goat anti-
Foxa2 (1:200, AbCam), rabbit anti-Pdx1 (1:5000; a gift
from Dr. D. Stoffers), goat anti-Somatostatin (1:5000;
Linco), rabbit anti-Somatostatin (1:50 in Antibody Diluent
Solution; Zymed), rabbit anti-Glucagon (Zymed), guinea
pig anti-Insulin (1:2000; Linco), goat anti-Ghrelin (1:200;
Santa Cruz), rabbit anti-PP (1:50; Zymed), rabbit anti-Pax6
(1:200; BabCO), goat anti-Amylase (1:200; Santa Cruz),
and rabbit anti-PC2 (1:100; Chemicon). The following
secondary antibodies were used: Cy3-conjugated donkey
anti-rabbit IgG (1:750; Jackson), Cy2-conjugate donkey
anti-guinea pig IgG (1:200; Jackson), Cy3-conjugated
donkey anti-goat (1:300; Jackson), and Cy2-conjugated
donkey anti-goat (1:300; Jackson).
Whole-mount immunostaining
Embryos at E9.5 were fixed in 4% PFA at RT for 30 min
and 48C for 1 h. Embryos were washed in PBS/0.1% Triton
X (PT) for 30 min at RT, then blocked in PT/5%BSA at 48C
O/N. Rabbit anti-Foxa2 antiserum was added at 1:1000 in
PT/5%BSA and the embryos were incubated O/N at 48C.
Embryos were washed in PT/1%BSA for 1.5 h at RT. Goat
anti-Rabbit-Alexa 488 (Molecular Probe) was added at
1:400 in PT/5%BSA for 2 h at RT. Embryos were washed in
PT/1%BSA for 1.5 h at RT, sectioned with vibratome, and
examined using confocal microscopy.
Whole-mount RNA in situ hybridization
Embryos were dissected from plugged females for E9.5
and E10.5. Whole-mount RNA in situ hybridization
procedure was described in Collombat et al. (2003). In
brief, embryos were fixed in 4% PFA and dehydrated
through a methanol series. Embryos were treated with 10
Ag/ml proteinase K and prehybridized at 70 8C for 1 h in
solution containing 50% formamide, 5 SSC pH4.5,50 Ag/ml yeast RNA, 1% SDS, and 50 Ag/ml heparin.
Digoxygenin glucagon probe was added to the same
solution at 1 Ag/ml and incubated overnight at 708C. After
series of washes, anti-DIG antibody was added overnight at
48C and the BM purple AP substrate (Roche) was used for
color detection.Results and discussion
Derivation of Foxa3Cre-transgenic mice
Targeting Cre-mediated gene deletion to the primitive gut
tube before the onset of liver and pancreas specification has
thus far been hampered by the lack of suitable promoter or
enhancer fragments. Commonly used Cre lines such as the
Albumin–Cre and Pdx1–Cre have an onset of expression
after liver and pancreas have been specified (Gu et al., 2002;
Herrera, 2000; Postic et al., 1999; Sund et al., 2000). To
overcome this limitation, we developed a new Cre-trans-
genic line that is active in the endoderm of the developing
gut before the onset of organogenesis. Foxa3 is one of the
few genes expressed early in the endoderm but not in other
tissues (Monaghan et al., 1993). We have previously
characterized the cis-regulatory elements essential for the
expression of Foxa3 in vivo and have shown that a 170-kb
yeast artificial chromosome (YAC Yg5) transgene mimics
the endogenous Foxa3 expression (Hiemisch et al., 1997).
A simplified map of the Yg5 YAC is shown in Fig. 1A. In
this YAC, the Foxa3 gene is flanked by ~100 kb upstream
and 60 kb downstream sequences. We have generated a
construct placing the Cre-recombinase cDNA into exon 2 of
the Foxa3 gene, preceded by an internal ribosome entry site
(Fig. 1). The modified Foxa3Cre YAC construct was used
for the derivation of transgenic mice by pronuclear injection
(Schedl et al., 1993). The presence of the transgene was
assessed by PCR analysis for the Cre cDNA (Fig. 1E). To
ascertain that the transgene had integrated intact into the
genome of the transgenic mice, we probed for the presence
of the yeast selectable markers LYS2 and TRP, which are
positioned in the right and left arm of the YAC, respectively
(Fig. 1E and data not shown).
To assess the activity of Cre recombinase under the
control of the cis-regulatory elements of Foxa3, we crossed
the Foxa3Cre mouse to a lacZ reporter mouse (Rosa26),
which indicates Cre activity by h-galactosidase staining
(Soriano, 1999). We expected to detect the expression of h-
galactosidase in all cells that normally express Foxa3.
When staining embryos for the activity, we found
expression in the anterior intestinal portal at E8.5 (Fig.
1F), in the foregut endoderm and its derivatives (hepatic
cords) at E9.5 (Fig. 1G), and in the dorsal and ventral
pancreatic buds at E10.5 (Fig. 1H), demonstrating that the
Foxa3Cre transgene reproduced the expression of the
endogenous Foxa3 locus and results in the efficient
excision of loxP targets.
Fig. 1. Derivation of the Foxa3Cre YAC and validation of the Foxa3Cre mice. (A) Map of the 170-kb Foxa3 YAC (termed Yg5). Exon 1 and Exon 2 are
represented as green and yellow boxes, respectively. The YAC telomeres are shown as arrows. (B) The targeting plasmid used for the modification of the YAC
and the site of recombination (not drawn to scale). The IRES–Cre cassette was placed within exon 2 of Foxa3. Selection for the presence of the Ura3 marker
(bpop-inQ) was achieved by growing transfected yeast cells on plates lacking uracil. (C) After homologous recombination, the Foxa3 YAC contains a partial
duplication of Foxa3 sequences and the IRES–CRE. Selection for the absence of Ura3 is achieved by plating on 5-fluoroorotic acid. Both the desired clones
(D) as well as the parental clone (B) were obtained and differentiated by PCR with primers A and B. (D) Map of the Foxa3Cre YAC that was used for the
generation of transgenic mice. (E) Foxa3Cre-transgenic mice were PCR genotyped for the presence of the Cre–cDNA and the LYS2 selection cassette present
in the right arm of the YAC. (F–H) Foxa3Cre mice were crossed to the Rosa26R reporter line (Soriano, 1999). E8.5, E9.5, and E10.5 embryos carrying both the
Foxa3Cre transgene and the Rosa26R allele were identified by PCR and stained for h-galactosidase. Blue staining indicates Cre-recombinase activity. The
Foxa3Cre transgene is active in all epithelial cells of the developing gut. (F) In whole-mount E8.5 embryos, Foxa3Cre activity was localized to the anterior
intestinal portal. (G) In sectioned E9.5 embryos, the developing gut (green arrow) as well as the hepatic primordium (red arrow) were stained. (H) In the E10.5
embryo, the gut tube as well as the dorsal (o) and ventral (*) pancreatic buds were positive for LacZ staining.
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Endoderm-spec i f ic Foxa2 knockout an imals
(Foxa2 loxP/loxP; Foxa3Cre) were obtained by breeding
Foxa3Cre-transgenic mice with Foxa2loxP/loxP mice (Sund
et al., 2000). The Foxa2loxP/+; Foxa3Cre offspring were
mated to Foxa2loxP/loxP homozygous mice to obtain the
four possible genotypes: Foxa2loxP/loxP; Foxa3Cre and
three littermate control groups: Foxa2loxP/+; Foxa3Cre,
Foxa2loxP/+, and Foxa2loxP/loxP.
To assess the onset and efficiency of Cre-mediated gene
deletion in Foxa2loxP/loxP; Foxa3Cre animals, Foxa2 protein
expression was examined in E9.5 embryos (Figs. 2A–F) and
postnatal day 1 (P1) pancreas (Figs. 2G–H) by immuno-
fluorescence. During early embryogenesis, Foxa2 expres-
sion is detected in the notochord, floorplate, and entire gut
tube of wild type E9.5 embryos (Figs. 2A and C). Similar
to control embryos, Foxa2 expression is present in both
the notochord and floorplate of Foxa2loxP/loxP; Foxa3Cre
mice. However, Foxa2-positive cells are reduced in the
foregut and completely absent in the midgut of E9.5Foxa2loxP/loxP; Foxa3Cre embryos (Figs. 2B and D). This
indicates that Foxa3Cre specifically deletes Foxa2 in the
endoderm without affecting Foxa2 expression in the
notochord and floorplate.
In order to assess whether Foxa2 is efficiently deleted in
the pancreatic primordium, we performed dual label
immunofluorescence with Foxa2 and Pdx1 antibodies on
E9.5 embryos. Pdx1 is one of the earliest markers of
pancreas development (Ahlgren et al., 1996). In the control
embryo, two populations of staining were observed: the
Pdx1+/Foxa2+ cells (orange) and Pdx1/Foxa2+ cells
(green) (Fig. 2E). The presence of Pdx1/Foxa2+ cells is
not surprising since it has been documented that not all
epithelial cells in the pancreatic bud are Pdx1 positive and
that these cells are still present in Pdx1-deficient animals
(Ahlgren et al., 1996). In contrast, Foxa2 expression is
almost completely absent in Pdx1+ and almost completely
deleted in Pdx1 cells in the pancreatic primordium of
Foxa2loxP/loxP; Foxa3Cre embryos (Fig. 2F). This demon-
strates that Foxa2 expression is efficiently deleted in the
pancreatic primordium as early as E9.5.
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the pancreas at later stages, we also examined Foxa2 protein
expression in P3 pancreas by immunofluorescence. In the
control pancreas, Foxa2 is found in both acini and islets
(Fig. 2G) whereas Foxa2 protein is not detected in these
tissues of Foxa2loxP/loxP; Foxa3Cre animals (Fig. 2H). This
demonstrates that the Foxa2 gene is completely absent in all
cell types of the pancreas by P3. Since both Foxa2 and
Foxa3 are also expressed in other endodermally derived
organs, we have also verified deletion of Foxa2 in liver,
stomach, and intestine in Foxa2loxP/loxP;Foxa3Cre mice
(data not shown). As a control, expression of Foxa2 in the
lung is still present in Foxa2loxP/loxP; Foxa3Cre mice sinceFoxa3 is not expressed in the lung (data not shown;
Monaghan et al., 1993).
Foxa2 is not required at the onset of pancreatic
development
It has been demonstrated both in vitro and in vivo that
Foxa2 controls Pdx1 gene expression in pancreatic h-cells
(Ben-Shushan et al., 2001; Cockell et al., 1995; Lee et al.,
2002b; Lin et al., 2002; Marshak et al., 2001; Sharma et al.,
1997; Wu et al., 1997). However, its role during early
formation of the pancreatic primordium, as well as the
regulation of Pdx1 expression in vivo, has not yet been
investigated due to the lack of suitable mouse models. To
address this question, we have examined Pdx1 expression in
the Foxa2loxP/loxP; Foxa3Cre embryo at E9.5 (Figs. 2E–F).
Since Foxa2 is expressed in the foregut before the formation
of the pancreatic primordium, we expected to see a change
in Pdx1 expression. However, not only is Pdx1 expression
not affected in the Foxa2loxP/loxP; Foxa3Cre embryo, the
pancreatic primordia are formed properly (Fig. 2F). This
indicates that Foxa2 is not required at the onset of
pancreatic development for Pdx1 expression. This may
reflect functional compensation for the loss of Foxa2
expression by Foxa1 or Foxa3.
Endoderm-specific deletion of Foxa2 leads to early lethality
and severe hypoglycemia
Foxa2loxP/loxP; Foxa3Cre mice were born alive with
reduced size when compared to their littermate control
groups (Fig. 3A) and most died by P3, with a few
surviving to P5. Of more than 200 offspring analyzed, no
Foxa2loxP/loxP; Foxa3Cre mouse has survived beyond P5.
Foxa2loxP/loxP; Foxa3Cre mice appeared dehydrated as
evidenced by reduced skin turgor; however, Foxa2loxP/loxP;
Foxa3Cre mice had milk in their stomachs, suggesting
normal suckling behavior.Fig. 2. Deletion of Foxa2 in Foxa2loxP/loxP; Foxa3Cre mice. Efficiency and
timing of Foxa2 deletion by Foxa3Cre were evaluated by immunofluor-
escence. Whole-mount immunofluorescence on E9.5 embryos using anti-
Foxa2 antibody was performed followed by vibratome sectioning. (A and
C) Foxa2 protein (green) was found in the floorplate, notochord, foregut,
and midgut of control embryos. (B and D) Expression of Foxa2 was still
detected in the floorplate and notochord. However, many of the cells in the
foregut were negative for Foxa2 staining (B) and Foxa2 expression was
completely deleted in the midgut (D). (E) Co-immunofluorescence staining
for Pdx1 (red) and Foxa2 (green) shows Foxa2 expression in both Pdx1+
(orange denoted by boQ) and Pdx1 (green denoted by b*Q) cells in the
pancreatic primordium of E9.5 control embryos. (F) Foxa2 expression is
deleted in both Pdx1+ (denoted by boQ) and Pdx1 cells except for one cell
(denoted by b*Q). (G–H) Expression of Foxa2 was also assessed by
immunofluorescence in the P3 pancreas. Insulin (green) and Foxa2 (red)
were found in the control pancreas (G), while Foxa2 protein was
completely deleted in both islets and acini in the Foxa2loxP/loxP; Foxa3Cre
pancreas (H). Abbreviations: floorplate (fp), notochord (nc), foregut (fg),
midgut (mg), pancreatic primordium (pp).
Fig. 3. Foxa2loxP/loxP; Foxa3Cre mice die shortly after birth and are
hypoglycemic. (A) Five-day-old (P5) Foxa2loxP/loxP; Foxa3Cre mouse
(bottom) and its control sibling (top). (B) P1–P3 mice of all possible
genotypes were sacrificed and blood glucose was measured. (C) Plasma
glucagon of pooled samples (~10 pups) from Foxa2loxP/loxP; Foxa3Cre and
control mice were measured by radioimmunoassay.
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regulating glucose homeostasis led us to examine glucose
levels in Foxa2loxP/loxP; Foxa3Cre mice and their control
littermates. Blood glucose levels were dramatically reduced
in Foxa2loxP/loxP; Foxa3Cre animals (Fig. 3B). Normally,
hypoglycemia triggers counter-regulatory glucagon secre-
tion; however, we observed a 50% reduction of plasma
glucagon when compared to control littermates (Fig. 3C).
This inappropriate reduction in circulating glucagon levels
in the face of significant hypoglycemia suggests a defect
in the production of this hormone due to reduced a-cell
number, glucagon biosynthesis, or glucagon secretion. We
have previously detected defects in glucose metabolism in
Foxa1- and Foxa3-deficient mice. Mice homozygous for
a null mutation in Foxa1 are hypoglycemic with reducedlevels of plasma glucagons, despite possessing the normal
complement of a-cells (Kaestner et al., 1999). In addition,
Foxa3-deficient mice exhibit moderate hypoglycemia after
a prolonged fast, which is mediated by a dramatic
decrease in the expression of the glucose transporter
GLUT 2 (Shen et al., 2001). Thus, a common role for the
Foxa genes is the protection of the organism from
hypoglycemia.
Foxa2loxP/loxP; Foxa3Cre animals have reduced numbers of
glucagon-positive cells
Since glucagon is synthesized in pancreatic a-cells, we
next examined glucagon expression in Foxa2 loxP/loxP;
Foxa3Cre and control pancreas by immunofluorescence
(Fig. 4). In control islets, numerous glucagon-positive cells
were found in the islet mantle (Figs. 4A,B and 5A,E),
whereas very few or no glucagon-positive cells were present
in the Foxa2loxP/loxP; Foxa3Cre islets (Figs. 4D,E and
5C,G). Next, we examined preproglucagon mRNA levels in
Foxa2loxP/loxP; Foxa3Cre and control pancreas by real-time
PCR analysis (Fig. 4M). Consistent with the absence of
glucagon immunoreactivity, preproglucagon transcripts
were reduced by 90% in the Foxa2loxP/loxP; Foxa3Cre
pancreas (Fig. 4M). Thus, Foxa2 is required for the
differentiation of mature glucagon-producing a-cells in the
pancreas. Thus, despite the expression of all three Foxa
genes in the endocrine pancreas, deletion of Foxa2 alone
results in perturbed pancreatic a-cell differentiation. While
in vitro all three Foxa genes can activate similar target
genes, our data suggest that they play different roles during
a-cell development in vivo. The differentiation of a-cells
requires the presence of Foxa2 as evidenced by reduced
levels of preproglucagon mRNA and protein in the
Foxa2loxP/loxP; Foxa3Cre pancreas. Although Foxa2 has
been shown to activate preproglucagon transcription in vitro
(Kaestner et al., 1999), it is likely that the lack of glucagon
production in the Foxa2loxP/loxP; Foxa3Cre pancreas is
secondary to a defect in a-cell maturation, as both Foxa1
and Foxa3 can also activate the preproglucagon promoter
(Kaestner et al., 1999).
Foxa2 is not required to specify the insulin, somatostatin,
pancreatic polypeptide, ghrelin, or acinar lineages
We investigated whether endocrine lineages other than a-
cells are dependent on Foxa2. To this end, we performed
immunostaining for insulin, somatostatin, pancreatic poly-
peptide, and ghrelin. Immunofluorescent staining for insulin
demonstrated that h-cells were specified in the absence of
Foxa2 (Figs. 4A–C, G–H and 5A–B, E–F). Somatostatin-
and pancreatic polypeptide-positive cells were found with
equal frequency in islets from Foxa2loxP/loxP; Foxa3Cre and
control mice (Figs. 4C, F, G, and J). Ghrelin is a hormone
that has been recently described to be expressed in the q
cells in the adult pancreas (Prado et al., 2004; Wierup et al.,
Fig. 4. Foxa2loxP/loxP; Foxa3Cre mice have few glucagon-positive cells and Foxa2 is required for the transcription of glucagon. Pancreas sections from P1
Foxa2loxP/loxP; Foxa3Cre and control mice were immunostained for islet and acinar cell markers. The images were captured by confocal microscopy. The
markers for endocrine pancreas were glucagon (a-cells), insulin (h-cells), somatostatin (y-cells), pancreatic polypeptide (PP-cells), and ghrelin (q-cells). The
marker for exocrine pancreas was amylase. (A and B) Normal insulin and glucagon expression were seen in the control pancreas. (D and E) Foxa2loxP/loxP;
Foxa3Cre mice have few or no glucagon-positive cells. Note that while some islets look normal (D), a majority of the islets are misshapen (E). y-, PP-, and q-
cells appear normal in both control (C, G, and H) and Foxa2loxP/loxP; Foxa3Cre (F, J, and K). Amylase expression is also found normal in the Foxa2loxP/loxP;
Foxa3Cre animal (I and L). Magnification is 400. (M) Quantitative RT-PCR analysis demonstrated a 90% reduction in glucagon expression. Bars represent
mean F SEM with P value b 0.05 by two-tailed Student’s t test. (N) mRNA levels of Brn4, Arx, and Pax6 are not different between Foxa2 loxP/loxP; Foxa3Cre
(white bars) and control (black bars) pancreata. HPRT was used as an internal control. n = 4 for both control and Foxa2loxP/loxP; Foxa3Cre animals.
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escence in the Foxa2 loxP/loxP; Foxa3Cre and control
pancreas. We found similar numbers of ghrelin-positive
cells surrounding the insulin-positive cells in each genotype
(Figs. 4H and K), suggesting that the ghrelin lineage is
independent of Foxa2. To determine whether the exocrine
cell lineage is affected in the Foxa2loxP/loxP; Foxa3Cre
pancreas, we examined amylase expression and found
similar expression the Foxa2loxP/loxP; Foxa3Cre and control
mice (Figs. 4I and L).
Foxa2loxP/loxP; Foxa3Cre animals have few mature a-cells
Endocrine cell differentiation occurs in a serial progres-
sion in which pancreatic precursors are first specified to
become endocrine progenitors that are marked by expres-
sion of Neurogenin 3 (Ngn3) (Apelqvist et al., 1999; Gu et
al., 2002; Herrera et al., 2002; Schwitzgebel et al., 2000).
Next, combinations of different transcription factors are
activated to cause these cells to adopt one of the five known
endocrine cell fates (Wilson et al., 2003). Thus, endocrine
cells differentiate as development proceeds and reach
maturity when they produce and secrete their respective
hormones. The phenotype caused by the lack of Foxa2
expression could represent a failure to specify the earliest
prea-cell lineage, a failure of an intermediate differentiation
step, or the lack of terminal differentiation to the mature
phenotype.
In order to address whether Foxa2 is required for the
initial specification of a-cell precursors, we examined
expression of prohormone convertase 2 (PC2). PC2 is anFig. 5. a-Cell progenitors are specified in the pancreas of the Foxa2loxP/loxP; Fox
pancreata were stained for insulin/glucagon (A, C, E, and G), insulin/somatostat
(green) and glucagon (red) of control (A and E) and Foxa2loxP/loxP; Foxa3Cre panc
and PC2-, insulin-, and somatostatin-positive cells (yellow) were present in simila
The numbers of insulin-negative and Pax6-positive cells were comparable betwee
for A–D is 400 and E–H is 1000.endopeptidase expressed in all endocrine precursors
beginning on day 10 of gestation, including those destined
to become mature a-cells (Marcinkiewicz et al., 1994).
PC2 is the only endopeptidase found in a-cells as early as
E10.0, and it is down-regulated in the adult (Marcinkie-
wicz et al., 1994). Since the majority of pancreatic
endocrine cell types are a-, h-, and y-cells at birth, we
examined the presence of these cell types by immunofluor-
escence using antibodies against insulin and glucagon (Figs.
5A and C) and PC2, insulin and somatostatin (Figs. 5B and
D) on serial sections of control and Foxa2 loxP/loxP;
Foxa3Cre pancreas. If Foxa2 is important during a-cell
lineage allocation or the survival of the lineage, then we
would expect no or few PC2-positive and insulin- and
somatostatin-negative cells. However, if Foxa2 is crucial
during a later step of a-cell differentiation, then we would
expect to find to see numerous PC2-positive/insulin- and
somatostatin-negative cells that do not stain for glucagon,
suggesting the presence of immature a-cells. In fact, the
latter scenario was observed in the Foxa2loxP/loxP; Foxa3-
Cre animals. In the control pancreas, normal insulin and
glucagon staining was observed (Fig. 5A) and PC2-
positive, insulin-negative, and somatostatin-negative cells
are either proglucagon- or glucagon-producing a-cells
(Fig. 5B). In the Foxa2loxP/loxP; Foxa3Cre pancreas, only
insulin but no glucagon staining was seen (Fig. 5C);
however, there were still numerous PC2-positive, insulin-,
and somatostatin-negative cells detected, consistent with
the presence of immature a-cells (Fig. 5D). Thus, Foxa2
is required for the terminal differentiation of pancreatic a-
cells, but not the initiation of the a-cell lineage.a3Cre mice. Adjacent sections of P1 Foxa2loxP/loxP; Foxa3Cre and control
in/PC2 (B and D), or insulin/Pax6 (F and H). Confocal images of insulin
reas (C and G). PC2-positive, insulin- and somatostatin-negative cells (red),
r numbers in both control (B) and Foxa2loxP/loxP; Foxa3Cre pancreas (D).
n the control (F) and Foxa2loxP/loxP; Foxa3Cre pancreas (H). Magnification
Fig. 6. Foxa2 is required for the maintenance but not the induction of first
wave glucagon-positive cells. RNA whole-mount in situ hybridization of
E9.5–E10.5 Foxa2loxP/loxP; Foxa3Cre and control embryos. (A–B) Expres-
sion of glucagon mRNA in the E9.5 Foxa2loxP/loxP; Foxa3Cre embryo is
similar to that of the control embryo. (C–D) Glucagon mRNA is reduced in
the E10.5 Foxa2loxP/loxP; Foxa3Cre embryo when compared to the control.
(E) A transverse section of the Foxa2loxP/loxP; Foxa3Cre embryo at the
pancreatic primordium plane showed residual glucagon mRNA. Dorsal
pancreatic bud is on the top. Pancreatic primordia are denoted by b*.Q
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Brn4, Pax6, and Arx during a-cell differentiation
Three transcription factors have been shown to be
involved in different stages of a-cell development based
on their expression patterns and loss-of-function pheno-
types. Brain 4 (Brn4), a POU homeodomain-containing
protein, is found in the glucagon-expressing cells of the
pancreatic buds at E10.0; however, mice lacking Brn4 do
not exhibit any pancreatic phenotype (Collombat et al.,
2003; Heller et al., 2004; Hussain et al., 1997; Phippard et
al., 1999). Pax6, a paired-box gene found in all endocrine
cells, is required for the specification of a-cells (St-Onge et
al., 1997). In addition, mutation of the Aristaless related
homeobox gene (Arx) results in an early onset loss of
mature pancreatic a-cells with an increase in h- and y-cell
numbers (Collombat et al., 2003). To place Foxa2 in the
a-cell differentiation hierarchy, we examined the expres-
sion of Brn4, Pax6, and Arx by real-time PCR analysis.
mRNA levels of these genes were unchanged between
Foxa2loxP/loxP; Foxa3Cre and control pancreas (Fig. 4N).
Since Brn4 in the pancreas is specific to a-cells, this
finding supports our notion that a-cells are specified in the
absence of Foxa2, even though they fail to differentiate
terminally. In addition, we examined expression of Pax6
protein by immunofluorescence (Figs. 5E–H). Control and
Foxa2loxP/loxP; Foxa3Cre pancreas were double stained for
insulin and glucagon (Figs. 5E and G) and insulin and
Pax6 on adjacent sections (Figs. 5F and H). This allowed
us to compare the numbers of Pax6-positive/insulin-negative
cells between Foxa2loxP/loxP; Foxa3Cre and control islets.
Expression of Pax6 appears similar in both insulin-positive
and insulin-negative endocrine cells between Foxa2loxP/loxP;
Foxa3Cre and control mice, again indicating that Pax6
expression is not dependent on Foxa2. Thus, we conclude
that Foxa2 does not act upstream of Arx, Pax6, and Brn4 in
the differentiation of a-cells.
First wave glucagon-producing cells require Foxa2 for their
maintenance
There are two populations of endocrine cells: the early
endocrine cells, which exist before E12.5, and cells that are
generated after the secondary transition (Ahlgren et al.,
1996). To determine whether loss of Foxa2 would affect the
early glucagon-positive cells, we examined glucagon
expression in E9.5 and E10.5 embryos by whole-mount
RNA in situ hybridization (Figs. 6A–E). At E9.5, normal
glucagon expression was detected in the Foxa2loxP/loxP;
Foxa3Cre embryo (Figs. 6A–B). When E10.5 embryos
were examined, we observed down-regulation of glucagon
expression in the Foxa2loxP/loxP; Foxa3Cre embryo; with
only a few glucagon-positive cells present in the dorsal
pancreatic bud (Figs. 6C–E). This indicates that the first
wave of glucagon-positive cells is partially dependent on
Foxa2.The shape and size of the islets are altered in the
Foxa2loxP/loxP; Foxa3Cre animals
In addition to the low number of terminally differentiated
a-cells, we also observed perturbed islet architecture in
Foxa2 loxP/loxP; Foxa3Cre pancreas (Fig. 4E). Control
pancreas exhibited roughly spherical islets (Figs. 4A–C
and 5A–B, E–F), but islets from Foxa2loxP/loxP; Foxa3Cre
animals were often irregularly shaped (Figs. 4E, K).
Furthermore, Foxa2loxP/loxP; Foxa3Cre islets displayed a
disorganized architecture with many small clusters of
endocrine cells embedded in the exocrine tissue (data not
shown). Although Foxa2 is also deleted in the acinar tissue
(Fig. 2F), we did not observe any obvious morphological
changes and differences in the amylase staining in the
Foxa2loxP/loxP; Foxa3Cre acini (Figs. 4I and L).
Foxa2 regulates multiple steps in pancreatic development
On the basis of the observations described above, we
propose a new model for Foxa2 action at multiple stages of
pancreatic development (Fig. 7). Previously, we have shown
that Foxa2 is an essential regulator of transcription in
mature pancreatic h-cells, as cell-type-specific gene ablation
leads to reduced expression of Pdx1 and of Sur1 and Kir6.2,
the subunits of the KATP channel, and perturbed insulin
secretion (Lantz et al., 2004; Lee et al., 2002b; Sund et al.,
Fig. 7. Model for the role of Foxa2 during pancreas differentiation. Foxa2 plays multiple roles during pancreas development. Foxa2 cooperates with an as yet
unidentified factor in the maintenance of Pdx1 in pancreatic h-cells. As shown here, the generation of early glucagon-containing cells is only partially
dependent on Foxa2. After the secondary transition, the terminal differentiation of a-cells does not occur in the absence of Foxa2.
C.S. Lee et al. / Developmental Biology 278 (2005) 484–495 4932001). As shown here, Foxa2 is not required at the onset of
pancreatic development to activate Pdx1 expression. This
maybe due to compensation by Foxa1 and Foxa3. However,
Foxa2 is a critical regulator of a-cell differentiation, acting
after the initial specification of the a-cell lineage. Due to the
paucity of markers, at present it is not known how many
intermediates exist between the Neurogenin 3-positive
endocrine precursor and the mature a-cell, or at which step
Foxa2 acts. As shown above, Foxa2 is required at a late
stage of a-cell development, as expressions of Arx, Brn4,
and Pax6 do not depend on Foxa2 (Fig. 7; black arrow). In
addition, Foxa2 is not absolutely required during delinea-
tion of the first wave of glucagon-positive cells (Fig. 7; grey
arrow). Involvement of a transcriptional regulator in several
steps of pancreatic development has been shown previously
for Pdx1, which is required for the early expansion of the
pancreatic primordium and in the mature h-cell (Ahlgren et
al., 1998; Jonsson et al., 1994; Offield et al., 1996). We have
shown here that similar to Pdx1, Foxa2 also plays multiple
roles in different endocrine cell types at different stages.
In conclusion, we have derived a novel endoderm-
specific Cre transgene (Foxa3Cre) that targets the earliest
stage of gut development and thus represents an important
new tool for the developmental genetic analysis of the
definite endoderm and its derivatives. By using this mouse,
we were able to delete Foxa2 in the pancreas as early as
E9.5 and demonstrate that Foxa2 is required for the terminal
differentiation of glucagon-producing a-cells, thereby iden-
tifying a novel function of Foxa2.Acknowledgments
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